Sichenzia Ross Ference Carmel LLP Represents BriaCell Therapeutics Corp. in $5 Million Registered Direct Offering

Press Release – New York, NY – May 17, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, in a $5 million registered direct offering.  The Company sold an aggregate of 2,402,935 common shares (or pre-funded warrants in lieu thereof) and warrants to purchase 2,402,935 common shares.  A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.  

The Sichenzia Ross Ference Carmel LLP team was led by partners Gregory Sichenzia, Avital Perlman, Glenn Burlingame, law clerk Soumya Cheedi, and senior paralegal Raquel Vazquez.